소외열대질환 치료 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Neglected Tropical Disease Treatment Market was valued at USD 3.7 billion in 2024 and is estimated to grow at a CAGR of 4.6% to reach USD 5.8 billion by 2034. This growth reflects the increasing global focus on combating neglected tropical diseases (NTDs), which remain a persistent health challenge across low-income and developing regions. NTDs refer to a group of 20 communicable diseases identified by the World Health Organization that mainly affect individuals in tropical and subtropical regions with limited access to essential healthcare. These diseases continue to place an immense burden on underserved communities, often leading to significant morbidity, long-term disability, and mortality.

Despite years of progress, NTDs still impact more than a billion people worldwide, with climate change, rapid urbanization, and increased human mobility further accelerating their spread. Health organizations, governments, and pharmaceutical companies are stepping up collaborative efforts through mass drug administration programs, awareness campaigns, and public-private partnerships to improve access to effective treatment options. Market dynamics are further influenced by advancements in diagnostics, growing investments in research, and the need to address antimicrobial resistance in tropical infections. The demand for reliable therapeutic interventions has never been more urgent as healthcare systems around the globe push for sustainable and inclusive solutions to curb the rising incidence of these debilitating diseases.

The Neglected Tropical Disease Treatment Market is segmented by disease type, with dengue, rabies, and trachoma among the top contributors. In 2024, the dengue segment alone accounted for 15% of the global market share. Dengue continues to emerge as a major health concern, affecting hundreds of millions every year and resulting in tens of thousands of deaths. The number of reported cases has seen a dramatic rise over the last five decades, reinforcing the critical need for effective treatments and prevention strategies. The market also addresses other high-burden conditions such as Buruli ulcer, yaws, and Chagas disease, each presenting unique treatment challenges and adding to the global healthcare load.

Treatment options for NTDs are broadly classified into drugs and vaccines. In 2024, the drug segment generated USD 2.7 billion in revenue. Anti-parasitic, antifungal, and antibiotic medications continue to be frontline tools in managing these diseases, playing a pivotal role in public health strategies to reduce infection rates and improve outcomes in vulnerable populations.

The U.S. Neglected Tropical Disease Treatment Market reached USD 1.33 billion in 2024, driven by increasing NTD prevalence in select regions and active support from government and philanthropic institutions. Organizations like the NIH are joining forces with global health bodies to expand treatment access and drive innovation.

Key players in the global market include Bayer, Astellas Pharma, and Eisai, which are leading innovations in drug and vaccine development for NTDs. These companies are prioritizing R&D, forming alliances with health organizations and governments, and aiming to deliver affordable, scalable solutions for affected communities.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of neglected tropical diseases
    • 3.2.1.2 Favorable government initiatives
    • 3.2.1.3 Growing awareness of neglected tropical diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of healthcare infrastructure
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dengue
• 5.3 Rabies
• 5.4 Trachoma
• 5.5 Buruli ulcer
• 5.6 Yaws
• 5.7 Leprosy
• 5.8 Chagas disease
• 5.9 Human African trypanosomiasis (sleeping sickness)
• 5.10 Leishmaniases
• 5.11 Soil-transmitted helminthiases
• 5.12 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Anti-parasite
  • 6.2.2 Antifungal
  • 6.2.3 Antibiotics
  • 6.2.4 Other drugs
• 6.3 Vaccines

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Astellas Pharma
• 10.2 Bayer
• 10.3 Bharat Biotech
• 10.4 Eisai
• 10.5 Gilead Sciences
• 10.6 GlaxoSmithKline
• 10.7 Johnson & Johnson
• 10.8 Merck
• 10.9 Novartis
• 10.10 Pfizer
• 10.11 Sanofi
• 10.12 Takeda Pharmaceutical
• 10.13 Tarsus Pharmaceuticals